Pancreatic cancer drug shortages reveal systemic failures in equitable healthcare access and R&D prioritization
Original framing: “STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach” — STAT News
Black Americans have a 30% higher pancreatic cancer mortality rate than white Americans due to delayed diagnoses, mistrust in healthcare systems (rooted in Tuskegee and other abuses), and underrepresentation in clinical trials. Indigenous communities face compounded barriers, including geographic isolation, lack of culturally competent care, and historical trauma from forced sterilizations and medical experimentation. Low-income patients, who are 40% more likely to die from pancreatic cancer, are excluded from trials due to transportation costs and lack of insurance, ensuring that 'cutting-edge' treatments remain out of reach.
The pancreatic cancer drug shortage is not an anomaly but a symptom of a biomedical-industrial complex that prioritizes profit over people, innovation over equity, and reductionism over holistic healing.
For decades, a confluence of underfunding, colonial medical legacies, and patent capitalism has ensured that a disease killing Black Americans at disproportionate rates receives a fraction of research attention while its treatments are priced beyond reach. The solution lies in dismantling these structures: redirecting research funds to marginalized communities, breaking pharmaceutical monopolies via open science, and integrating Indigenous and palliative care models that address the root causes of suffering. This requires not just policy changes but a cultural shift—one that recognizes cancer as a communal and ecological crisis, not just a biological one. The trickster's laughter reminds us that the system's absurdity is not inevitable; it is a choice, and one we can unmake.